Active substance
Sodium bicarbonate
- SFDA 24
- US FDA 19
- Health Canada 12
- US price lines 2
- NHS prices 7
- Safety 14
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| 5%W/V SODIUM BICARBONATE intravenous infusion B.P | 5 % | Solution for infusion · Intravenous use | 1 Bottle | SAR 10.70 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| BASIC BICARBONATE CONCENTRATE 8.125% INF | 8.125 % | Solution · Intravenous use | 1 Bag | SAR 35.50 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| SODIUM BICARBONATE 650GM POWDER | 650 g | Powder for concentrate for solution for haemodialysis · Parenteral use | 1 Bottle | SAR 9.05 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| SODIUM BICARBONATE 7.5% I.V SOLUTION | 7.5 % | Solution · Intravenous use | 1 Bottle | SAR 5.70 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| SODIUM BICARBONATE 7.5% I.V SOLUTION | 7.5 % | Solution · Intravenous use | 1 Bottle | SAR 6.85 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| SODIUM BICARBONATE 7.5% I.V SOLUTION | 7.5 % | Solution · Intravenous use | 1 Bottle | SAR 10.50 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| SODIUM BICARBONATE 7.5% I.V SOLUTION | 7.5 % | Solution · Intravenous use | 1 Bottle | SAR 5.45 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| SODIUM BICARBONATE 8.4% INF. | 8.4 % | Solution for infusion · Intravenous use | 1 Bottle | SAR 16.00 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| SODIUM BICARBONATE 8.4% INF. | 8.4 % | Solution for infusion · Intravenous use | 1 Bottle | SAR 8.00 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| SODIUM BICARBONATE 8.4% INJ. | 8.4 % | Solution for injection · Intravenous use | 1 Pre-filled syringe | SAR 7.85 | Generic · Prescription | HOSPIRA INC | Valid |
| SODIUM BICARBONATE 8.4% INJ. | 8.4 % | Solution for injection · Intravenous use | 1 Pre-filled syringe | SAR 8.20 | Generic · Prescription | HOSPIRA INC | Valid |
| SODIUM BICARBONATE 840GM POWDER | 840 g | Powder for concentrate for solution for haemodialysis · Parenteral use | 1 Bottle | SAR 9.80 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| BASIC BICARBONATE CONCENTRATE 8.4% INFUS | 8.4 % | Solution · Intravenous use | 1 Bag | SAR 37.95 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Withdrawn by MAH · Not Marketed |
| HEMODIALYSIS GRADE SOD.BICARB(3P001)840G | 840 g | Concentrate for solution for haemodialysis · Parenteral use | 1 Bottle | SAR 13.10 | Generic · Prescription | ARABIAN DIAGNOSTIC AND MEDICAL COMPANY | Withdrawn by MAH · Not Marketed |
| HEMODIALYSIS GRADE SOD.BICARB(3P003)650G | 650 g | Concentrate for solution for haemodialysis · Parenteral use | 1 Bottle | SAR 10.15 | Generic · Prescription | ARABIAN DIAGNOSTIC AND MEDICAL COMPANY | Withdrawn by MAH · Not Marketed |
| SOD.BICARBONATE 4.2% INJ | 4.2 % | Solution for injection · Intravenous use | 1 Bottle | SAR 20.15 | Generic · Prescription | B. BRAUN | Withdrawn by MAH · Not Marketed |
| SODIUM BICARB. SOLUTION CAT.NO 3F-005 | 8.4 % | Solution · Intravenous use | 1 Bag | SAR 19.30 | Generic · Prescription | ARABIAN DIAGNOSTIC AND MEDICAL COMPANY | Withdrawn by MAH · Not Marketed |
| SODIUM BICARBONATE 5% INF. | 5 % | Solution for infusion · Intravenous use | 1 Bottle | SAR 13.80 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Withdrawn by MAH · Not Marketed |
| SODIUM BICARBONATE 5% INFUSION | 5 % | Solution for injection · Intravenous use | 1 Bag | SAR 13.80 | Generic · Prescription | HOSPIRA INC | Withdrawn by MAH · Not Marketed |
| SODIUM BICARBONATE 7.5% EMG.SYRINGE | 7.5 % | Solution · Intravenous use | 1 Pre-filled syringe | SAR 34.45 | Generic · Prescription | HOSPIRA INC | Withdrawn by MAH · Not Marketed |
| SODIUM BICARBONATE 8.4% INF. | 8.4 % | Solution · Intravenous use | 1 Bottle | SAR 8.35 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Withdrawn by MAH · Not Marketed |
| SODIUM BICARBONATE 8.4% INJ | 8.4 % | Solution for injection · Intravenous use | 10 Ampoule | SAR 30.95 | Generic · Prescription | B. BRAUN | Withdrawn by MAH · Not Marketed |
| SODIUM BICARBONATE 8.4% INJ | 8.4 % | Solution for injection · Intravenous use | 1 Bottle | SAR 21.75 | Generic · Prescription | B. BRAUN | Withdrawn by MAH · Not Marketed |
| SODIUM BICARBONATE 8.4% INJ | 8.4 % | Solution for injection · Intravenous use | 1 Bottle | SAR 8.85 | Generic · Prescription | B. BRAUN | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANESTHESIA-SUPPORTIVE AGENTS/ CARDIAC ARREST, CARDIOVASCULAR EMERGENCIES AND/OR DYSRHYTHMIAS; BURKITT`S LYMPHOMA-URINE ALKALINIZATION; DIARRHEA; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-URINE ALKALINIZATION; DISORDERS OF PURINE AND PYRIMIDINE METABOLISM; MANTLE CELL LYMPHOMA-URINE ALKALINIZATION; PEDIATRIC B-CELL LYMPHOMA-HBV PROPHYLAXIS; Septic Shock; T-CELL LYMPHOMA-URINE ALKALINIZATION
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SODIUM BICARBONATE | 2.5MEQ/5ML (0.5MEQ/ML) | solution · intravenous | HOSPIRA | Prescription | 4 Mar 2016 |
| SODIUM BICARBONATE | 44.6MEQ/50ML (0.9MEQ/ML); 50MEQ/50ML (1MEQ/ML) | solution · intravenous | HOSPIRA | Prescription | 6 Mar 2017 |
| SODIUM BICARBONATE | 10MEQ/10ML (1MEQ/ML) | solution · intravenous | HOSPIRA | Prescription | 6 Mar 2017 |
| SODIUM BICARBONATE | 5MEQ/10ML (0.5MEQ/ML) | solution · intravenous | HOSPIRA | Prescription | 7 Mar 2017 |
| SODIUM BICARBONATE | 50MEQ/50ML (1MEQ/ML) | solution · intravenous | INTL MEDICATION SYS | Prescription | 19 Sep 2017 |
| SODIUM BICARBONATE | 50MEQ/50ML (1MEQ/ML) | solution · intravenous | HOSPIRA | Prescription | 26 Sep 2017 |
| SODIUM BICARBONATE | 5MEQ/10ML (0.5MEQ/ML); 44.6MEQ/50ML (0.9MEQ/ML); 10MEQ/10ML (1MEQ/ML); 50MEQ/50ML (1MEQ/ML) | solution · intravenous | EXELA PHARMA | Prescription | 20 Jun 2019 |
| SODIUM BICARBONATE | 50MEQ/50ML (1MEQ/ML) | solution · intravenous | OMNIVIUM PHARMS | Prescription | 15 Jun 2023 |
| SODIUM BICARBONATE | 50MEQ/50ML (1MEQ/ML) | solution · intravenous | STERISCIENCE | Prescription | 28 Jun 2023 |
| SODIUM BICARBONATE | 50MEQ/50ML (1MEQ/ML) | solution · intravenous | LONG GROVE PHARMS | Prescription | 27 Feb 2024 |
| SODIUM BICARBONATE | 50MEQ/50ML (1MEQ/ML) | solution · intravenous | ADAPTIS | Prescription | 26 Jun 2025 |
| SODIUM BICARBONATE | 2.5MEQ/5ML (0.5MEQ/ML); 50MEQ/50ML (1MEQ/ML) | solution · intravenous | FRESENIUS KABI USA | Prescription | 25 Aug 2025 |
| SODIUM BICARBONATE | 50MEQ/50ML (1MEQ/ML) | solution · intravenous | AMNEAL | Prescription | 13 Jan 2026 |
| SODIUM BICARBONATE | 5MEQ/10ML (0.5MEQ/ML); 10MEQ/10ML (1MEQ/ML); 50MEQ/50ML (1MEQ/ML) | solution · intravenous | ASPIRO | Prescription | 15 Apr 2026 |
| SODIUM BICARBONATE | 50MEQ/50ML (1MEQ/ML) | solution · intravenous | MILLA PHARMS | Prescription | 6 Jul 2026 |
| SODIUM BICARBONATE | 150MEQ/1000ML (0.15MEQ/ML) | solution · intravenous | AMNEAL | Prescription | 9 Jul 2026 |
| SODIUM BICARBONATE | 150MEQ/1000ML (0.15MEQ/ML) | solution · intravenous | BAXTER HLTHCARE CORP | Prescription | 14 Aug 2026 |
| SODIUM BICARBONATE IN PLASTIC CONTAINER | 44.6MEQ/50ML (0.9MEQ/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 50MEQ/50ML (1MEQ/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution · intravenous | ABBOTT | Discontinued | 3 Jun 1986 |
| SODIUM BICARBONATE | 44.6MEQ/50ML (0.9MEQ/ML); 50MEQ/50ML (1MEQ/ML) | solution · intravenous | HOSPIRA | Discontinued | 9 Nov 2005 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| BIBAG | 02325586 | 650 G / BAG | POWDER FOR SOLUTION · HAEMODIALYSIS | FRESENIUS MEDICAL CARE CANADA INC |
| BIBAG | 02487756 | 900 G / BAG | POWDER FOR SOLUTION · HAEMODIALYSIS | FRESENIUS MEDICAL CARE CANADA INC |
| BICARBONATE CONCENTRATE B38 | 02248934 | 80.7 G / L | SOLUTION · HAEMODIALYSIS | CHIEF MEDICAL SUPPLIES LTD |
| BICARBONATE CONCENTRATE D17000 | 00691623 | 81.3 G / L | SOLUTION · HAEMODIALYSIS | VANTIVE ULC |
| BICART | 02403498 | 720 G / CARTRIDGE | POWDER · HAEMODIALYSIS | VANTIVE ULC |
| BICART | 02403501 | 1250 G / CARTRIDGE | POWDER · HAEMODIALYSIS | VANTIVE ULC |
| HEMACART | 02325772 | 650 G / CARTRIDGE | POWDER FOR SOLUTION · HAEMODIALYSIS | CHIEF MEDICAL SUPPLIES LTD |
| SODIUM BICARBONATE INJECTION USP | 00261998 | 84 MG / ML | SOLUTION · INTRAVENOUS | PFIZER CANADA ULC |
| SODIUM BICARBONATE INJECTION USP | 02467585 | 84 MG / ML | SOLUTION · INTRAVENOUS | OMEGA LABORATORIES LIMITED |
| SODIUM BICARBONATE INJECTION USP | 02516225 | 84 MG / ML | SOLUTION · INTRAVENOUS | JAMP PHARMA CORPORATION |
| SODIUM BICARBONATE INJECTION USP | 02541904 | 84 MG / ML | SOLUTION · INTRAVENOUS | STERIMAX INC |
| SODIUM BICARBONATE INJECTION, USP | 02486636 | 84 MG / ML | SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | SODIUM BICARBONATE 8.4% VIAL | $0.154 | per ML | 12 Aug 2026 |
| US NADAC | SODIUM BICARBONATE 8.4% VIAL | $0.15869 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Sodium bicarbonate 420mg/5ml (1mmol/ml) oral solution sugar free | £35.82 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Sodium bicarbonate 420mg/5ml (1mmol/ml) oral solution sugar free | £179.28 | 500 ml | 1 Oct 2026 |
| NHS Drug Tariff | Sodium bicarbonate 500mg capsules | £5.40 | 56 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Sodium bicarbonate 500mg gastro-resistant capsules | £18.75 | 100 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Sodium bicarbonate 8.4% (1mmol/ml) solution for injection 100ml bottles | £127.00 | 10 bottle | 1 Oct 2026 |
| NHS Drug Tariff | Sodium bicarbonate 8.4% (1mmol/ml) solution for injection 10ml ampoules | £208.44 | 10 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Sodium bicarbonate 8.4% (1mmol/ml) solution for injection 250ml bottles | £127.00 | 10 bottle | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 18 Jul 2023 ZEGERID — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Jul 2023 ZEGERID — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Nov 2022 ZEGERID OTC — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 1 Nov 2022 ZEGERID OTC — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 14 May 2021 GOLYTELY — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 May 2021 COLYTE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 May 2021 COLYTE WITH FLAVOR PACKS — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 May 2021 COLYTE-FLAVORED — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 May 2021 NULYTELY — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 May 2021 NULYTELY-FLAVORED — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 1 May 2019 NORMOCARB HF 25 — safety-related labeling change
Labeling sections changed: Use in Specific Populations - US FDA 1 May 2019 NORMOCARB HF 35 — safety-related labeling change
Labeling sections changed: Use in Specific Populations - US FDA 30 Jun 2017 PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations - US FDA 30 Jun 2017 PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations
Combinations containing Sodium bicarbonate
- Acetylsalicylic acid + sodium bicarbonate
- Omeprazole + sodium bicarbonate
- Paracetamol + sodium bicarbonate
- Calcium carbonate + magnesium hydroxide + sodium bicarbonate
- Calcium carbonate + sodium alginate + sodium bicarbonate
- Citric acid + magnesium oxide + sodium bicarbonate
- Citric acid + magnesium sulfate + sodium bicarbonate
- Citric acid + sodium bicarbonate + tartaric acid
- Magnesium chloride + sodium bicarbonate + sodium chloride
- Magnesium sulfate + sodium bicarbonate + tartaric acid
- Citric acid + sodium bicarbonate + sodium citrate + tartaric acid
- Citric acid + sodium bicarbonate + tartaric acid + tri
- Macrogol + potassium chloride + sodium bicarbonate + sodium chloride
- Polyethylene glycol + potassium chloride + sodium bicarbonate + sodium chloride
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.